Below are the financial statements of Ajanta Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of INR | 2025 as of 2025-03-31 | 2024 as of 2024-03-31 |
|---|---|---|
| Assets | — | — |
| Non-current assets | — | — |
| Property, plant and equipment | 16,248.7a | 13,841.3a |
| Capital work-in-progress | 1,762.7a | 2,564.5a |
| Right-of-use assets | 906.3a | 804a |
| Other intangible assets (other than self generated) | 465.2a | 146.6a |
| Financial assets | — | — |
| Investments | 252.4a | 185.8a |
| Other non-current financial assets | 92.5a | 93.6a |
| Deferred tax assets (net) | 1,864.3a | 1,344.5a |
| Income tax assets (net) | 127.1a | 94.4a |
| Total non-current assets | 21,719.2a | 19,074.7a |
| Current assets | — | — |
| Inventories | 9,038.5a | 8,283.6a |
| Financial assets | — | — |
| Investments | 4,387.1a | 3,300.5a |
| Trade receivables | 11,827.4a | 12,468.4a |
| Cash and cash equivalents | 1,751.2a | 1,294.9a |
| Bank balances other than cash and cash equivalents | 11.2a | 12.8a |
| Loans | 25.4a | 339.6a |
| Other financial assets | 23.2a | 190.2a |
| Other current assets | 1,233a | 1,330.7a |
| Assets classified as held for sale | 133.3a | 88.5a |
| Total current assets | 28,430.3a | 27,309.2a |
| Total assets | 50,149.5a | 46,383.9a |
| Equity and liabilities | — | — |
| Equity | — | — |
| Equity share capital | 250.7a | 252.7a |
| Other equity | 37,652.2a | 35,420.9a |
| Total equity | 37,902.9a | 35,673.6a |
| Liabilities | — | — |
| Non-current liabilities | — | — |
| Financial liabilities | — | — |
| Lease liabilities | 347.2a | 235.2a |
| Other financial liabilities | 10.5a | 13.7a |
| Other non-current liabilities | 20a | 23.4a |
| Provisions | 802.7a | 395.4a |
| Deferred tax liabilities (net) | 1,105.2a | 1,085a |
| Total non-current liabilities | 2,285.6a | 1,752.7a |
| Current liabilities | — | — |
| Financial liabilities | — | — |
| Borrowings | 25.9a | 14.9a |
| Lease liabilities | 101.1a | 102.7a |
| Trade payables | — | — |
| Total outstanding dues of micro enterprises and small enterprises; and | 215.5a | 206.4a |
| Total outstanding dues of creditors other than micro enterprises and small enterprises. | 4,326.5a | 4,425.6a |
| Other financial liabilities | 3,742a | 2,980.3a |
| Other current liabilities | 911.2a | 597.3a |
| Provisions | 233.5a | 177.6a |
| Income tax liabilities (net) | 405.3a | 447.7a |
| Liabilities classified as held for sale | 0a | 5.1a |
| Total current liabilities | 9,961a | 8,957.6a |
| Total liabilities | 12,246.6a | 10,710.3a |
| Total equity and liabilities | 50,149.5a | 46,383.9a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ajanta Pharma’s data sources below and access millions more through our Disclosure Search.